Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2013, Article ID 671935, 9 pages
http://dx.doi.org/10.1155/2013/671935
Case Report

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

1st Department of Neurology, Athens National and Kapodistrian University, Aeginition Hospital, 11528 Athens, Greece

Received 26 March 2013; Accepted 29 April 2013

Academic Editors: T. K. Banerjee, A. Fasano, R. Hashimoto, and M. Swash

Copyright © 2013 E. Andreadou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Tracey, L. Klareskog, E. H. Sasso, J. G. Salfeld, and P. P. Tak, “Tumor necrosis factor antagonist mechanisms of action: a comprehensive review,” Pharmacology and Therapeutics, vol. 117, no. 2, pp. 244–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. P. Sfikakis and G. C. Tsokos, “Towards the next generation of anti-TNF drugs,” Clinical Immunology, vol. 141, no. 3, pp. 231–235, 2011. View at Google Scholar
  3. G. Kollias, E. Douni, G. Kassiotis, and D. Kontoyiannis, “On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease,” Immunological Reviews, vol. 169, pp. 175–194, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Caminero, M. Comabella, and X. Montalban, “Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story,” Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Lin, D. Ziring, S. Desai et al., “TNFα blockade in human diseases: an overview of efficacy and safety,” Clinical Immunology, vol. 126, no. 1, pp. 13–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. Karampetsou, S. N. C. Liossis, and P. P. Sfikakis, “TNF-α antagonists beyond approved indications: stories of success and prospects for the future,” QJM, vol. 103, no. 12, pp. 917–928, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. L. Hyrich, A. J. Silman, K. D. Watson, and D. P. M. Symmons, “Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety,” Annals of the Rheumatic Diseases, vol. 63, no. 12, pp. 1538–1543, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. T. Borchers, N. Leibushor, G. S. Cheema, S. M. Naguwa, and M. E. Gershwin, “Immune mediated adverse effects of biological used in the treatment of rheumatic diseases,” Journal of Autoimmunity, vol. 37, no. 4, pp. 273–288, 2011. View at Google Scholar
  9. F. Van Hauwermeiren, R. E. Vandenbroucke, and C. Libert, “Treatment of TNF mediated disease by selective inhibition of soluble TNF or TNFR1,” Cytokine & Growth Factor Reviews, vol. 22, no. 5-6, pp. 311–319, 2011. View at Google Scholar
  10. B. W. Van Oosten, F. Barkhof, L. Truyen et al., “Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2,” Neurology, vol. 47, no. 6, pp. 1531–1534, 1996. View at Google Scholar · View at Scopus
  11. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, “TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study,” Neurology, vol. 53, no. 3, pp. 457–465, 1999. View at Google Scholar
  12. N. Mohan, E. T. Edwards, T. R. Cupps et al., “Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides,” Arthritis & Rheumatism, vol. 44, no. 12, pp. 2862–2869, 2001. View at Google Scholar
  13. H. J. Freeman and B. Flak, “Demyelination-like syndrome in Crohn's disease after infliximab therapy,” Canadian Journal of Gastroenterology, vol. 19, no. 5, pp. 313–316, 2005. View at Google Scholar · View at Scopus
  14. M. Tanno, I. Nakamura, S. Kobayashi, K. Kurihara, and K. Ito, “New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients,” Clinical Rheumatology, vol. 25, no. 6, pp. 929–933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. H. Robinson, M. C. Genovese, and L. W. Moreland, “Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?” Arthritis & Rheumatism, vol. 44, no. 9, pp. 1977–1983, 2001. View at Google Scholar
  16. M. Cisternas, M. Gutiérrez, S. Jacobelli, N. Mohan, and T. R. Cupps, “Successful rechallenge with anti-tumor necrosis factor α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.,” Arthritis and Rheumatism, vol. 46, no. 11, pp. 3107–3109, 2002. View at Google Scholar · View at Scopus
  17. M. D. Magnano, W. H. Robinson, and M. C. Genovese, “Demyelination and inhibition of tumor necrosis factor (TNF),” Clinical and Experimental Rheumatology, vol. 22, no. 5, supplement 35, pp. S134–S140, 2004. View at Google Scholar · View at Scopus
  18. N. L. Sicotte and R. R. Voskuhl, “Onset of multiple sclerosis associated with anti-TNF therapy,” Neurology, vol. 57, no. 10, pp. 1885–1888, 2001. View at Google Scholar · View at Scopus
  19. T. Ruiz-Jimeno, A. Carvajal, C. Mata, and E. Aurrecoechea, “Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab,” Journal of Rheumatology, vol. 33, no. 7, pp. 1457–1458, 2006. View at Google Scholar · View at Scopus
  20. D. S. Titelbaum, A. Degenhardt, and R. P. Kinkel, “Anti-tumor necrosis factor alpha-associated multiple sclerosis,” American Journal of Neuroradiology, vol. 26, no. 6, pp. 1548–1550, 2005. View at Google Scholar · View at Scopus
  21. E. Dubcenco, C. A. Ottaway, D. L. Chen, and J. P. Baker, “Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 5, pp. 565–566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Toussirot, E. Pertuiset, A. Martin et al., “Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance,” Journal of Rheumatology, vol. 33, no. 5, pp. 1027–1029, 2006. View at Google Scholar · View at Scopus
  23. C. F. Pfueller, E. Seipelt, F. Zipp, and F. Paul, “Multiple sclerosis following etanercept treatment for ankylosing spondylitis,” Scandinavian Journal of Rheumatology, vol. 37, no. 5, pp. 397–399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Winkelmann, R. Patejdl, S. Wagner, R. Benecke, and U. K. Zettl, “Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy,” Journal of Neurology, vol. 255, no. 6, supplement 6, pp. 109–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mignarri, M. T. Dotti, C. Battisti, I. Vallone, and A. Federico, “Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLA-B27 positive patient,” Neurological Sciences, vol. 30, no. 4, pp. 329–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Bernatsky, C. Renoux, and S. Suissa, “Demyelinating events in rheumatoid arthritis after drug exposures,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1691–1693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Solomon, R. I. Spain, M. C. Kruer, and D. Bourdette, “Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors,” Multiple Sclerosis Journal, vol. 17, no. 12, pp. 1472–1487, 2011. View at Google Scholar
  28. A. Fromont, J. De Seze, M. C. Fleury, J. F. Maillefert, and T. Moreau, “Inflammatory demyelinating events following treatment with anti-tumor necrosis factor,” Cytokine, vol. 45, no. 2, pp. 55–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at Google Scholar
  30. G. Kassiotis and G. Kollias, “Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination,” Journal of Experimental Medicine, vol. 193, no. 4, pp. 427–434, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. K. W. Selmaj and C. S. Raine, “Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro,” Annals of Neurology, vol. 23, no. 4, pp. 339–346, 1988. View at Google Scholar · View at Scopus
  32. T. Nomura, Y. Abe, H. Kamada et al., “Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice,” Journal of Controlled Release, vol. 149, no. 1, pp. 8–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Berg, J. Lampa, S. Rogberg, R. Van Vollenhoven, and L. Klareskog, “Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors,” Annals of the Rheumatic Diseases, vol. 60, no. 2, pp. 133–139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. E. S. Molloy and L. H. Calabrese, “Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies,” Arthritis & Rheumatism, vol. 64, no. 9, pp. 3043–3051, 2012. View at Publisher · View at Google Scholar
  35. M. Ramos-Casals, Roberto-Perez-Alvarez, C. Diaz-Lagares, M. J. Cuadrado, and M. A. Khamashta, “Autoimmune diseases induced by biological agents: a double-edged sword?” Autoimmunity Reviews, vol. 9, no. 3, pp. 188–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Nozaki, R. M. Silver, D. E. Stickler et al., “Neurological deficits during treatment with tumor necrosis factor-alpha antagonists,” The American Journal of the Medical Sciences, vol. 342, no. 5, pp. 352–355, 2011. View at Google Scholar
  37. L. J. Mejico, “Infliximab-associated retrobulbar optic neuritis,” Archives of Ophthalmology, vol. 122, no. 5, pp. 793–794, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Faillace, J. R. de Almeida, and J. F. de Carvalho, “Optic neuritis after infliximab therapy,” Rheumatology International, vol. 33, no. 4, pp. 1101–1103, 2013. View at Publisher · View at Google Scholar
  39. M. C. Fernández-Espartero, B. Pérez-Zafrilla, A. Naranjo et al., “Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review,” Seminars in Arthritis and Rheumatism, vol. 40, no. 4, pp. 330–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Gomez-Gallego, J. Meca-Lallana, and A. Fernandez-Barreiro, “Multiple sclerosis onset during etanercept treatment,” European Neurology, vol. 59, no. 1-2, pp. 91–93, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Atzeni, P. Sarzi-Puttini, D. Dell' Acqua et al., “Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study,” Arthritis Research & Therapy, vol. 8, no. 1, article R3, 2006. View at Google Scholar · View at Scopus
  42. N. Cikes, D. Bosnic, and M. Sentic, “Non-MS autoimmune demyelination,” Clinical Neurology and Neurosurgery, vol. 110, no. 9, pp. 905–912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Lozeron, C. Denier, C. Lacroix, and D. Adams, “Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-a-blocker therapy,” Archives of Neurology, vol. 66, no. 4, pp. 490–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. I. S. J. Shin, A. N. Baer, H. J. Kwon, E. J. Papadopoulos, and J. N. Siegel, “Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy,” Arthritis and Rheumatism, vol. 54, no. 5, pp. 1429–1434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. N. M. Nielsen, T. Westergaard, K. Rostgaard et al., “Familial risk of multiple sclerosis: a nationwide cohort study,” American Journal of Epidemiology, vol. 162, no. 8, pp. 774–778, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Cohen, D. Robinson Jr., C. Paramore, K. Fraeman, K. Renahan, and M. Bala, “Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002,” Inflammatory Bowel Diseases, vol. 14, no. 6, pp. 738–743, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Ledingham and C. Deighton, “Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001),” Rheumatology, vol. 44, no. 2, pp. 157–163, 2005. View at Publisher · View at Google Scholar · View at Scopus